In the BioHarmony Drug Report Database
Dacomitinib
Vizimpro (dacomitinib) is a small molecule pharmaceutical. Dacomitinib was first approved as Vizimpro on 2018-09-27. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. It is known to target receptor tyrosine-protein kinase erbB-4, epidermal growth factor receptor, and receptor tyrosine-protein kinase erbB-2. Vizimpro’s patents are valid until 2028-08-26 (FDA).
Trade Name
|
Vizimpro |
|---|---|
Common Name
|
dacomitinib |
ChEMBL ID
|
CHEMBL2110732 |
Indication
|
non-small-cell lung carcinoma |
Drug Class
|
Tyrosine kinase inhibitors |
Image (chem structure or protein)